Kang Won Lee; Dae Won Jun

doi:10.4166/kjg.2015.65.3.194

Journal List > Korean J Gastroenterol > v.65(3) > 1007352

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee and Jun: Nonselective β Blockers in Decompensated Cirrhosis: When to Start and for How Long?

Research Update

Korean J Gastroenterol 2015;65(3):194-196.

Published online: 4 October 2015

DOI: https://doi.org/10.4166/kjg.2015.65.3.194

Nonselective β Blockers in Decompensated Cirrhosis: When to Start and for How Long?

Kang Won Lee, Dae Won Jun

Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

Correspondence to: Dae Won Jun, Department of Gastroenterology, Hanyang University Medical Center, 222 Wangsimni-ro, Seongdong-gu, Seoul 133-791, Korea. Tel: +82-2-2290-8304, Fax: +82-2-2298-9183, E-mail: noshin@hanyang.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis

References

1. Sersté T, Melot C, Francoz C, et al. Deleterious effects of be-ta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010; 52:1017–1022.

2. Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014; 146:1680–1690.e1.

3. Hernández-Gea V, Aracil C, Colomo A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012; 107:418–427.

4. Senzolo M, Cholongitas E, Burra P, et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009; 29:1189–1193.

5. Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012; 61:967–969.

6. Ruiz-del-Arbol L, Urman J, Fernández J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003; 38:1210–1218.

7. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in de-termining prognosis. Gastroenterology. 2010; 139:1246–1256. e5.

8. Sersté T, Francoz C, Durand F, et al. Beta-blockers cause para-centesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011; 55:794–799.

9. Galbois A, Das V, Thabut D, et al. Beta-blockers have no effect on outcomes in patients with cirrhosis and severe infections. Hepatology. 2011; 53:1412–1413.

10. Bendtsen F, Henriksen JH, S⊘rensen TI. Propranolol and haemodynamic response in cirrhosis. J Hepatol. 1991; 13:144–148.

11. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005; 353:2254–2261.

12. Krag A, Bendtsen F, Henriksen JH, M⊘ller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010; 59:105–110.

TOOLS

Similar articles